OraSure Technologies, Inc. OSUR NASDAQ · Healthcare · United States
$3.62 +0.00% +$0.00
Summary
38 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $148.2M against $11.6M.
- It bought back its own shares for $15.0M in the last fiscal year, 6.0% of its market value.
What to watch
- Revenue fell by 33% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 7.7% a year over 5 years. Over the last 3 years it fell by 33% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $48.5M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 9
- Sell 0
Today's price within the analysts' price targets
The average target of $7 is 93% above today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product And Services 95%
- Other Revenues 5.2%
By region
- UNITED STATES 68%
- Africa 21%
- Europe 6.4%
- Other Foreign Countries 4.7%
Product And Services brings in 95% of revenue.
Segments in detail